Safety, tolerability, and pharmacokinetics of repeated oral doses of 2-hydroxybenzylamine acetate in healthy volunteers: a double-blind, randomized, placebo-controlled clinical trial

Table 4 Mean salicylic acid pharmacokinetic parameters after oral doses of 2-hydroxybenzylamine

Parameter	2-Hydroxybenzylamine acetate dose
	500 mg (n = 6)		750 mg (n = 5–6)
	Day 1 (first dose)	Day 15 (last dose)	Day 1 (first dose)	Day 15 (last dose)
T_max (h)	5.00 ± 1.10	3.50 ± 1.22	4.67 ± 1.03	3.20 ± 1.79
C_max (ng/mL)	7635 ± 2112	11,382 ± 4118	12,092 ± 2619	12,768 ± 3703
AUC_0–8h (h·ng/mL)	42,458 ± 12,070	75,288 ± 28,095	65,935 ± 13,775	81,826 ± 28,120
AUC (h·ng/mL)		123,075 ± 55,044		117,842 ± 41,615

C_max, maximum observed plasma concentration; T_max, time to reach C_max; AUC, area under the concentration-time curve from zero to infinity; AUC_0–8, area under the dosing interval curve.

ISSN: 2050-6511